Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)

NCT ID: NCT00163540

Last Updated: 2015-05-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-05-31
• Study Completion Date: 2005-06-30

Brief Summary

The objective of this study is to investigate the immunogenicity and safety of a third vaccination with FSME-IMMUN 0.5 ml given approximately 12 months after the second vaccination in Study 225. In Study 225, two vaccinations were given using a rapid immunization schedule 12 ± 2 days apart.

Conditions

Encephalitis, Tick-borne

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Interventions

Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Male and female subjects who:
• received 2 vaccinations with FSME-IMMUN 0.5 ml during Study 225
• understand the nature of the study, agree to its provisions and provide written informed consent
• are clinically healthy (i.e. the physician would have no reservation vaccinating with FSME-IMMUN 0.5 ml outside the scope of the clinical trial)
• have a negative pregnancy test result at the first medical examination (if female and capable of bearing children)
• agree to employ adequate birth control measures for the duration of the study (if female and capable of bearing children)
• agree to keep a Subject Diary

Exclusion Criteria

Subjects who:

• have already been administered a third TBE vaccination elsewhere since receiving two vaccinations in Study 225
• have a history of infection with, or vaccination against, other flaviviruses since participation in Study 225 (e.g. yellow fever, dengue fever, japanese B encephalitis)
• have had an allergic reaction to one of the components of the vaccine since participation in Study 225
• suffer from a disease (e.g. autoimmune disease, immunodeficiency) or are undergoing a form of treatment (e.g., systemic corticosteroids) that can be expected to influence immunological functions
• have a known or suspected problem with drug or alcohol abuse (>4 liters wine/week or equivalent doses of other alcoholic beverages)
• have donated blood or plasma within 30 days of study entry
• have received a blood transfusion or immunoglobulins within 30 days of study entry
• are known to be HIV positive (an HIV test is not required specifically for this study)
• are simultaneously participating in another clinical trial including administration of an investigational product
• have participated in any other clinical study within 6 weeks prior to study start
• have participated in another Baxter vaccine study in the past 6 months (with the exception of follow-up studies)
• For female subjects: pregnancy or lactation

• Minimum Eligible Age: 17 Years
• Maximum Eligible Age: 66 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Pfizer

INDUSTRY

Sponsor Role: lead

Principal Investigators

Baxter BioScience Investigator, MD

Role: PRINCIPAL_INVESTIGATOR

Baxter BioScience

Locations

SGS Biopharma Research Unit Stuivenberg

Antwerp, , Belgium

Countries

Belgium

References

Orlinger KK, Hofmeister Y, Fritz R, Holzer GW, Falkner FG, Unger B, Loew-Baselli A, Poellabauer EM, Ehrlich HJ, Barrett PN, Kreil TR. A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans. J Infect Dis. 2011 Jun 1;203(11):1556-64. doi: 10.1093/infdis/jir122.

Reference Type: DERIVED

PMID: 21592984 (View on PubMed)

Other Identifiers

690501

Identifier Type: -

Identifier Source: org_study_id